February 17, 2011
OncoTartis, Inc. is incorporated as a NY corporation located in Buffalo, NY. Roswell Park Cancer Institute (RPCI) and Children's Cancer Institute Australia (CCIA) contributed founding IP and are shareholders of the company. BioProcess Capital Ventures, Moscow, Russia is a financial investor that committed a funding sufficient to support OncoTartis, Inc. operations for 3 years.
January 30, 2012
The Grant Committee of Skolkovo Innovation Center, a scientific and technological center for the development and commercialization of advanced technologies (Moscow, Russia) ratified Grant Agreement on financing of Oncotartis research program with an approximately $5M grant.
February 27, 2013
OncoTartis relocates to the Innovation Center at Buffalo Niagara Medical Campus. Company’s laboratories and offices occupy 3,500 square feet at 640 Ellicott Street, Buffalo, New York.
May 1, 2013
Skolkovo Foundation approves the second tranche of OncoTartis grant after OncoTartis met or exceeded the Grant's milestones. .
November 19, 2013
The Innovation Center started conversion of adjacent to OncoTartis facilities space into biological laboratories. Upon the project completion that is expected in March 2014, new laboratories (2,300 square feet) will be fully equipped and added to existing OncoTartis research facilities.
March 1, 2014
OncoTartis moves into the new custom-built laboratories equipped for a regular scientific bench work, as well as a special facility for testing response of the cultured cancer cells to discovered anti-cancer compounds.
May 16, 2014
OncoTartis completed process development for scaling up and manufacturing its OT-82 drug candidate on a kilo scale. The work was done at Nanosyn, Inc., a Santa Clara, CA based chemistry CRO.
October 30, 2014
OncoTartis completed a non-GLP formal toxicology study of OT-82 on rats (21 day) and monkeys (28 days) and successfully determined a safe dose range for human clinical studies. These studies are planned to be repeated under GLP conditions starting in 1Q15.
January 28, 2015
A panel of external scientific experts convened by the Skolkovo Foundation peer reviewed and approved OncoTartis' Final Report summarizing successful development of novel clinical candidate against a broad spectrum of hematopoietic malignancies.